These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Y1 receptor of neuropeptide Y as a glial marker in proliferative vitreoretinopathy and diseased human retina. Cantó Soler MV; Gallo JE; Dodds RA; Hökfelt T; Villar MJ; Suburo AM Glia; 2002 Sep; 39(3):320-4. PubMed ID: 12203398 [TBL] [Abstract][Full Text] [Related]
25. Expression of myofibroblast activation molecules in proliferative vitreoretinopathy epiretinal membranes. Abu El-Asrar AM; Missotten L; Geboes K Acta Ophthalmol; 2011 Mar; 89(2):e115-21. PubMed ID: 20528783 [TBL] [Abstract][Full Text] [Related]
26. Resveratrol inhibits epithelial-mesenchymal transition of retinal pigment epithelium and development of proliferative vitreoretinopathy. Ishikawa K; He S; Terasaki H; Nazari H; Zhang H; Spee C; Kannan R; Hinton DR Sci Rep; 2015 Nov; 5():16386. PubMed ID: 26552368 [TBL] [Abstract][Full Text] [Related]
27. Changes in retinal gene expression in proliferative vitreoretinopathy: glial cell expression of HB-EGF. Hollborn M; Tenckhoff S; Jahn K; Iandiev I; Biedermann B; Schnurrbusch UE; Limb GA; Reichenbach A; Wolf S; Wiedemann P; Kohen L; Bringmann A Mol Vis; 2005 Jun; 11():397-413. PubMed ID: 15988409 [TBL] [Abstract][Full Text] [Related]
28. BMP7 antagonizes proliferative vitreoretinopathy through retinal pigment epithelial fibrosis in vivo and in vitro. Yao H; Ge T; Zhang Y; Li M; Yang S; Li H; Wang F FASEB J; 2019 Mar; 33(3):3212-3224. PubMed ID: 30383450 [TBL] [Abstract][Full Text] [Related]
29. Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy. Mori K; Gehlbach P; Ando A; Dyer G; Lipinsky E; Chaudhry AG; Hackett SF; Campochiaro PA Invest Ophthalmol Vis Sci; 2002 Jun; 43(6):2001-6. PubMed ID: 12037011 [TBL] [Abstract][Full Text] [Related]
30. Evidence of chronic inflammation in retina excised after relaxing retinotomy for anterior proliferative vitreoretinopathy. Limb GA; Chignell AH; Woon H; Green W; Cole CJ; Dumonde DC Graefes Arch Clin Exp Ophthalmol; 1996 Apr; 234(4):213-20. PubMed ID: 8964525 [TBL] [Abstract][Full Text] [Related]
31. A new model of proliferative vitreoretinopathy. Frenzel EM; Neely KA; Walsh AW; Cameron JD; Gregerson DS Invest Ophthalmol Vis Sci; 1998 Oct; 39(11):2157-64. PubMed ID: 9761295 [TBL] [Abstract][Full Text] [Related]
32. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Lei H; Hovland P; Velez G; Haran A; Gilbertson D; Hirose T; Kazlauskas A Invest Ophthalmol Vis Sci; 2007 May; 48(5):2335-42. PubMed ID: 17460299 [TBL] [Abstract][Full Text] [Related]
33. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Cui JZ; Chiu A; Maberley D; Ma P; Samad A; Matsubara JA Eye (Lond); 2007 Feb; 21(2):200-8. PubMed ID: 16531976 [TBL] [Abstract][Full Text] [Related]
34. Preoperative aqueous humour flare values do not predict proliferative vitreoretinopathy in patients with rhegmatogenous retinal detachment. Mulder VC; Tode J; van Dijk EH; Purtskhvanidze K; Roider J; van Meurs JC; Treumer F Br J Ophthalmol; 2017 Sep; 101(9):1285-1289. PubMed ID: 28077370 [TBL] [Abstract][Full Text] [Related]
35. Effect of Robo1 on retinal pigment epithelial cells and experimental proliferative vitreoretinopathy. Huang L; Xu Y; Yu W; Li Y; Chu L; Dong J; Li X Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3193-204. PubMed ID: 20071679 [TBL] [Abstract][Full Text] [Related]
36. Effect of Methotrexate on an In Vitro Patient-Derived Model of Proliferative Vitreoretinopathy. Amarnani D; Machuca-Parra AI; Wong LL; Marko CK; Stefater JA; Stryjewski TP; Eliott D; Arboleda-Velasquez JF; Kim LA Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):3940-3949. PubMed ID: 28777835 [TBL] [Abstract][Full Text] [Related]
37. Disease pathways in proliferative vitreoretinopathy: an ongoing challenge. Tosi GM; Marigliani D; Romeo N; Toti P J Cell Physiol; 2014 Nov; 229(11):1577-83. PubMed ID: 24604697 [TBL] [Abstract][Full Text] [Related]
38. Noggin producing, MyoD-positive cells are crucial for eye development. Gerhart J; Pfautz J; Neely C; Elder J; DuPrey K; Menko AS; Knudsen K; George-Weinstein M Dev Biol; 2009 Dec; 336(1):30-41. PubMed ID: 19778533 [TBL] [Abstract][Full Text] [Related]
39. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Hinton DR; He S; Jin ML; Barron E; Ryan SJ Eye (Lond); 2002 Jul; 16(4):422-8. PubMed ID: 12101449 [TBL] [Abstract][Full Text] [Related]
40. Rhegmatogenous retinal detachment and conventional surgical treatment. Golubovic M Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2013; 34(1):161-6. PubMed ID: 23917750 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]